NOTE: This article is provided free of charge by The Washington Post.
The Food and Drug Administration’s decision to give emergency authorization for convalescent plasma as a treatment for novel coronavirus patients — touted as a historic breakthrough by President Trump on Sunday — is raising doubts among some experts who say certain claims of its effectiveness are dubious or wrong. View the post here.